Abstract
RNA interference (RNAi) is an attractive phenomenon for practical use that specifically inhibits gene expression and is carried out by small double-stranded RNAs (dsRNAs) including small interfering RNA (siRNA) or short hairpin RNA (shRNA). In addition, RNAi is of great interest for clinical use to cure refractory diseases related to the expression of a specific gene. To achieve gene silencing in the body, a sufficient amount of dsRNA must be delivered and internalized into target cells. However, dsRNAs have a large molecular weight and net negative charge, which limits their membrane-permeating ability. Moreover, dsRNAs are rapidly degraded by endonucleses in the body. Therefore, for the efficient delivery of dsRNAs, many approaches based on drug delivery systems have been carried out. In this review, we focus on recent reports about the application of functional peptides and proteins designed for the efficient delivery of dsRNAs.
Keywords: RNA interference (RNAi), gene delivery, double-stranded RNA (dsRNA), cell penetrating peptide (CPP), atelocollagen, double-stranded RNA-binding domain (dsRBD)
Current Topics in Medicinal Chemistry
Title: Enhanced Gene Delivery and/or Efficacy by Functional Peptide and Protein
Volume: 9 Issue: 12
Author(s): Tomoyuki Okuda, Yasuhisa Kawaguchi and Hirokazu Okamoto
Affiliation:
Keywords: RNA interference (RNAi), gene delivery, double-stranded RNA (dsRNA), cell penetrating peptide (CPP), atelocollagen, double-stranded RNA-binding domain (dsRBD)
Abstract: RNA interference (RNAi) is an attractive phenomenon for practical use that specifically inhibits gene expression and is carried out by small double-stranded RNAs (dsRNAs) including small interfering RNA (siRNA) or short hairpin RNA (shRNA). In addition, RNAi is of great interest for clinical use to cure refractory diseases related to the expression of a specific gene. To achieve gene silencing in the body, a sufficient amount of dsRNA must be delivered and internalized into target cells. However, dsRNAs have a large molecular weight and net negative charge, which limits their membrane-permeating ability. Moreover, dsRNAs are rapidly degraded by endonucleses in the body. Therefore, for the efficient delivery of dsRNAs, many approaches based on drug delivery systems have been carried out. In this review, we focus on recent reports about the application of functional peptides and proteins designed for the efficient delivery of dsRNAs.
Export Options
About this article
Cite this article as:
Okuda Tomoyuki, Kawaguchi Yasuhisa and Okamoto Hirokazu, Enhanced Gene Delivery and/or Efficacy by Functional Peptide and Protein, Current Topics in Medicinal Chemistry 2009; 9 (12) . https://dx.doi.org/10.2174/156802609789630857
DOI https://dx.doi.org/10.2174/156802609789630857 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
c-Myc and Downstream Targets in the Pathogenesis and Treatment of Cancer
Recent Patents on Anti-Cancer Drug Discovery Role of Oxidative Stress in Hepatitis C Virus Induced Hepatocellular Carcinoma
Current Cancer Drug Targets Melatonin and Melatoninergic Drugs as Therapeutic Agents: Ramelteon and Agomelatine, the Two Most Promising Melatonin Receptor Agonists
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Poor Safety and Tolerability Hamper Reaching a Potentially Therapeutic Dose in the Use of Thalidomide for Alzheimer’s Disease: Results from a Double-Blind, Placebo-Controlled Trial
Current Alzheimer Research The PAX8 / PPARγ Fusion Oncogene as a Potential Therapeutic Target in Follicular Thyroid Carcinoma
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Chemodiversity in Freshwater and Terrestrial Cyanobacteria – A Source for Drug Discovery
Current Drug Targets Recent Advances in Chalcone-Based Anticancer Heterocycles: A Structural and Molecular Target Perspective
Current Medicinal Chemistry Integrins and Cancer: Gene Expression, Epigenetics and Metastasis
Current Genomics Eupatilin Inhibits the Proliferation and Migration of Prostate Cancer Cells through Modulation of PTEN and NF-κB Signaling
Anti-Cancer Agents in Medicinal Chemistry New 2-Imino-2H-Chromene-3(N-aryl)carboxamides as Potential Cytotoxic Agents
Anti-Cancer Agents in Medicinal Chemistry Intranasal Fluorescent Nanocrystals for Longitudinal <i>In Vivo</i> Evaluation of Cerebral Microlesions
Pharmaceutical Nanotechnology Anticancer Agents Derived from Natural Products
Mini-Reviews in Medicinal Chemistry Molecular Targeted Therapies in the Management of Head and Neck Squamous Cell Carcinoma: Recent Developments and Perspectives
Anti-Cancer Agents in Medicinal Chemistry Synthesis of Unsymmetrical C5-Curcuminoids as Potential Anticancer Agents
Letters in Drug Design & Discovery Targeting SphK1 as a New Strategy against Cancer
Current Drug Targets The miR-183/96/182 Cluster Regulates Oxidative Apoptosis and Sensitizes Cells to Chemotherapy in Gliomas
Current Cancer Drug Targets Membrane Fusion Mediated Targeted Cytosolic Drug Delivery Through scFv Engineered Sendai Viral Envelopes
Current Molecular Medicine Specific Targeting of Akt Kinase Isoforms: Taking the Precise Path for Prevention and Treatment of Cancer
Current Drug Targets Disorders of Consciousness and Electrophysiological Treatment Strategies: A Review of the Literature and New Perspectives
Current Pharmaceutical Design Comparison of the Mean Minimum Dose of Bolus Oxytocin for Proper Uterine Contraction during Cesarean Section
Current Clinical Pharmacology